Iovance Biotherapeutics
IOVA
301 hedge funds and large institutions have $799M invested in Iovance Biotherapeutics in 2025 Q1 according to their latest regulatory filings, with 56 funds opening new positions, 100 increasing their positions, 93 reducing their positions, and 54 closing their positions.
25% more call options, than puts
Call options by funds: $8.21M | Put options by funds: $6.57M
8% more repeat investments, than reductions
Existing positions increased: 100 | Existing positions reduced: 93
4% more first-time investments, than exits
New positions opened: 56 | Existing positions closed: 54
0% more funds holding
Funds holding: 301 → 301 (0)
6.13% less ownership
Funds ownership: 79.26% → 73.13% (-6.1%)
55% less capital invested
Capital invested by funds: $1.79B → $799M (-$989M)
71% less funds holding in top 10
Funds holding in top 10: 7 → 2 (-5)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ICM
Invenomic Capital Management
Boston,
Massachusetts
|
+$28.3M |
| 2 |
LFCM
Long Focus Capital Management
San Juan,
Puerto Rico
|
+$21.2M |
| 3 |
UBS AM
Chicago,
Illinois
|
+$20M |
| 4 |
Renaissance Technologies
New York
|
+$18.1M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$11.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$48.5M |
| 2 |
ACA
Avoro Capital Advisors
New York
|
-$25.9M |
| 3 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
-$20.1M |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
-$13.5M |
| 5 |
Man Group
London,
United Kingdom
|
-$12.3M |
IOVA Hedge Fund Activity: Q1 2025 in Review
301 of the 7,458 institutional investors tracked by Wall St. Rank reported a position in Iovance Biotherapeutics (IOVA) for Q1 2025, worth a combined $799M — down 55% from $1.79B a quarter earlier.
Buyers outnumbered sellers: 56 funds opened new IOVA positions and 54 closed out — a net gain of 2 holders — while 100 added to existing stakes and 93 trimmed.
The largest buyer was Invenomic Capital Management, opening a new position worth an estimated $28.3M. The largest seller was Perceptive Advisors, cutting an estimated $48.5M.
- 301 institutional investors held Iovance Biotherapeutics (IOVA) as of Q1 2025, unchanged from Q4 2024.
- Funds reported $799M of Iovance Biotherapeutics stock for Q1 2025, down 55% quarter-over-quarter.
- 56 funds opened new Iovance Biotherapeutics positions in Q1 2025 and 54 closed out, a net change of +2 holders.
- The largest Iovance Biotherapeutics buyer in Q1 2025 was Invenomic Capital Management, an estimated $28.3M added.
- The largest Iovance Biotherapeutics seller in Q1 2025 was Perceptive Advisors, an estimated $48.5M sold.
Based on aggregated 13F filings for Q1 2025.